Jessica Lee Mueller, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enteric Nervous System | 5 | 2024 | 213 | 1.330 |
Why?
|
| Hirschsprung Disease | 3 | 2024 | 163 | 1.070 |
Why?
|
| Neuroglia | 3 | 2024 | 960 | 0.910 |
Why?
|
| Agrin | 1 | 2024 | 75 | 0.910 |
Why?
|
| Neural Stem Cells | 3 | 2024 | 895 | 0.810 |
Why?
|
| Hypophosphatemia | 1 | 2018 | 93 | 0.590 |
Why?
|
| Pancreatic Fistula | 1 | 2018 | 149 | 0.580 |
Why?
|
| Hepatectomy | 1 | 2021 | 588 | 0.560 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 516 | 0.480 |
Why?
|
| Phosphates | 1 | 2018 | 765 | 0.480 |
Why?
|
| Pancreatectomy | 1 | 2018 | 825 | 0.450 |
Why?
|
| Lipase | 1 | 2016 | 321 | 0.440 |
Why?
|
| Neurogenesis | 4 | 2024 | 865 | 0.440 |
Why?
|
| Gastrectomy | 1 | 2018 | 693 | 0.430 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 697 | 0.420 |
Why?
|
| Neural Crest | 3 | 2024 | 278 | 0.410 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1273 | 0.400 |
Why?
|
| Cell Movement | 1 | 2024 | 5216 | 0.390 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 551 | 0.390 |
Why?
|
| Interleukins | 1 | 2016 | 796 | 0.360 |
Why?
|
| Neurons | 2 | 2024 | 9519 | 0.300 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 1483 | 0.300 |
Why?
|
| Myenteric Plexus | 2 | 2024 | 49 | 0.300 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1033 | 0.290 |
Why?
|
| Liver Transplantation | 2 | 2016 | 2403 | 0.280 |
Why?
|
| Liver Cirrhosis | 2 | 2016 | 1962 | 0.260 |
Why?
|
| Neuroblastoma | 2 | 2024 | 1266 | 0.250 |
Why?
|
| Stem Cell Transplantation | 2 | 2024 | 1602 | 0.230 |
Why?
|
| Ganglia | 1 | 2023 | 86 | 0.210 |
Why?
|
| Risk Adjustment | 2 | 2017 | 603 | 0.200 |
Why?
|
| Enterocolitis | 1 | 2022 | 106 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6401 | 0.180 |
Why?
|
| Benchmarking | 2 | 2017 | 1059 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7885 | 0.160 |
Why?
|
| Awards and Prizes | 1 | 2023 | 365 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2021 | 15889 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 2041 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 16053 | 0.130 |
Why?
|
| Republic of Korea | 1 | 2018 | 592 | 0.130 |
Why?
|
| Colon | 1 | 2024 | 1803 | 0.130 |
Why?
|
| Biomedical Research | 2 | 2023 | 3463 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 2 | 2017 | 1941 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2021 | 3438 | 0.120 |
Why?
|
| Paracentesis | 1 | 2015 | 99 | 0.120 |
Why?
|
| Apolipoproteins | 1 | 2016 | 328 | 0.120 |
Why?
|
| Specialties, Surgical | 1 | 2019 | 393 | 0.110 |
Why?
|
| Histones | 1 | 2023 | 2603 | 0.110 |
Why?
|
| SEER Program | 1 | 2018 | 1473 | 0.110 |
Why?
|
| Mice | 6 | 2024 | 82072 | 0.100 |
Why?
|
| Albumins | 1 | 2015 | 577 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 682 | 0.100 |
Why?
|
| Interferons | 1 | 2016 | 720 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2714 | 0.090 |
Why?
|
| Animals | 7 | 2024 | 169335 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2018 | 2942 | 0.090 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 2542 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2023 | 3592 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2024 | 19023 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2016 | 1344 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 40261 | 0.070 |
Why?
|
| Massachusetts | 1 | 2021 | 8894 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 12095 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 4835 | 0.070 |
Why?
|
| Humans | 17 | 2024 | 768970 | 0.070 |
Why?
|
| General Surgery | 1 | 2018 | 1722 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 30046 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2016 | 2382 | 0.060 |
Why?
|
| Graft Survival | 1 | 2016 | 3888 | 0.060 |
Why?
|
| Genotype | 2 | 2016 | 13048 | 0.060 |
Why?
|
| Survival Rate | 1 | 2018 | 12873 | 0.060 |
Why?
|
| Integrin alpha2 | 1 | 2023 | 39 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18435 | 0.060 |
Why?
|
| Female | 9 | 2023 | 397515 | 0.060 |
Why?
|
| Male | 8 | 2023 | 365203 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2016 | 3070 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 2336 | 0.050 |
Why?
|
| Research Design | 1 | 2019 | 6214 | 0.050 |
Why?
|
| Weaning | 1 | 2023 | 102 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2016 | 4492 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8384 | 0.050 |
Why?
|
| Neurites | 1 | 2024 | 390 | 0.050 |
Why?
|
| Schwann Cells | 1 | 2023 | 196 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 10400 | 0.050 |
Why?
|
| Chromatin | 2 | 2024 | 2981 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 74976 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2023 | 11684 | 0.050 |
Why?
|
| Middle Aged | 5 | 2018 | 223737 | 0.050 |
Why?
|
| Liver | 1 | 2016 | 7578 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4363 | 0.040 |
Why?
|
| Technology | 1 | 2022 | 296 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 794 | 0.040 |
Why?
|
| Lysine | 1 | 2023 | 1000 | 0.040 |
Why?
|
| Disease Progression | 1 | 2016 | 13674 | 0.040 |
Why?
|
| Nerve Regeneration | 1 | 2024 | 799 | 0.040 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2023 | 633 | 0.040 |
Why?
|
| Aged | 4 | 2018 | 171786 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 59739 | 0.040 |
Why?
|
| Universities | 1 | 2023 | 1005 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 24333 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2023 | 1218 | 0.030 |
Why?
|
| United States | 3 | 2023 | 73186 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2024 | 2885 | 0.030 |
Why?
|
| Sample Size | 1 | 2019 | 848 | 0.030 |
Why?
|
| Feces | 1 | 2022 | 1510 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2023 | 1667 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2023 | 2414 | 0.030 |
Why?
|
| Intestines | 1 | 2024 | 1911 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 65480 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39394 | 0.030 |
Why?
|
| Ascites | 1 | 2015 | 338 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 41808 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 60131 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 1159 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 9565 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 81903 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8748 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3914 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 1515 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 17173 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 223851 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1812 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10765 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5369 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 30265 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7460 | 0.010 |
Why?
|
| Child | 1 | 2022 | 80960 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54962 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 89244 | 0.000 |
Why?
|